Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. (PTGX) on August 13, 2020, covering events occurring on August 11 and August 12, 2020. The filing addresses changes to the Company's Board of Directors.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
- Director Resignation: Chaitan Khosla, Ph.D., resigned from the Board of Directors and the Nominating and Corporate Governance Committee on August 11, 2020. The resignation was not due to any disagreement with the Company.
- Director Appointment: Sarah O'Dowd was appointed as a Class II director on August 12, 2020, serving until the 2021 Annual Meeting of Stockholders or until a successor is elected.
- Independence: The Board determined that Ms. O'Dowd is an independent director under Nasdaq listing standards.
Compensation and Governance Details
Ms. O'Dowd's compensation package under the Company's Non-Employee Director Compensation Policy includes:
- Cash Compensation: $40,000 annually, paid in quarterly installments prorated for partial service months.
- Initial Stock Option: An option to purchase 30,000 shares of common stock, vesting in 36 equal monthly installments contingent on continuous service.
- Annual Stock Options: Eligibility for annual grants of options to purchase an additional 15,000 shares, vesting at the earlier of one year or the next annual meeting.
- Committee Service: No committee appointments were determined at the time of filing; additional cash compensation would apply if appointed to a committee.
- Indemnification: The Company will enter into a standard indemnification agreement with Ms. O'Dowd.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Sarah O'Dowd, against Nasdaq governance standards.
- Confirm the vesting schedule and exercise price of the 30,000-share initial option grant to Ms. O'Dowd in subsequent filings.
- Monitor future announcements regarding Ms. O'Dowd's specific committee assignments and any associated additional compensation.
- Note that the departure of Dr. Khosla was voluntary and unrelated to any disagreement with the Company.